MedTrace Logo

Antiproteinuric Effects of Liraglutide Treatment

NCT02545738 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2016-08-10

No results posted yet for this study

Summary

The purpose of the study is to determine the effect of Liraglutide on albuminuria in type 2 diabetes.

Conditions

  • Diabetic Kidney Disease

Interventions

DRUG

Liraglutide

active treatment

DRUG

placebo

placebo

Sponsors & Collaborators

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • Steno Diabetes Center Copenhagen

    lead OTHER

Principal Investigators

  • Peter Rossing, MD · Steno Diabetes Center Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02545738 on ClinicalTrials.gov